Nucleozin is primarily recognized for its antiviral properties, particularly in the context of influenza virus inhibition. It functions by targeting the nucleoprotein of the influenza virus, which is crucial for viral replication. By binding to this protein, Nucleozin disrupts the virus's ability to replicate its genetic material, thereby halting the infection process. This makes it a potential candidate for the development of antiviral therapies, especially in cases where influenza strains show resistance to conventional treatments like neuraminidase inhibitors. Research is ongoing to explore its efficacy and safety in clinical settings, with the aim of providing an alternative or complementary option for managing influenza infections.